Kate Van Brunt
Overview
Explore the profile of Kate Van Brunt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schechter M, Sabater-Anaya N, Oster G, Weycker D, Wu H, Arteaga-Solis E, et al.
Pulm Ther
. 2023 Oct;
9(4):479-498.
PMID: 37874528
Introduction: Cystic fibrosis (CF) is a life-limiting genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is a CFTR modulator (CFTRm) that targets...
2.
Lee T, Sawicki G, Altenburg J, Millar S, Geiger J, Jennings M, et al.
J Cyst Fibros
. 2022 Dec;
22(3):402-406.
PMID: 36581485
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be safe and efficacious in people with cystic fibrosis (CF) with ≥ 1 F508del-CFTR allele in Phase 3 clinical trials. ELX/TEZ/IVA treatment led to improved...
3.
Fajac I, Daines C, Durieu I, Goralski J, Heijerman H, Knoop C, et al.
J Cyst Fibros
. 2022 Sep;
22(1):119-123.
PMID: 36114142
Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be safe and efficacious in people with cystic fibrosis (CF) heterozygous for F508del and a minimal function mutation (F/MF) or homozygous for F508del (F/F) in...
4.
Sawicki G, Van Brunt K, Booth J, Bailey E, Millar S, Konstan M, et al.
J Cyst Fibros
. 2021 Jul;
21(1):96-103.
PMID: 34289939
Background: People with cystic fibrosis (CF) heterozygous for F508del-CFTR and a minimal function CFTR mutation (F/MF) that results in no CFTR protein or results in CFTR protein that is not...
5.
Idris I, Peng X, He X, Liu D, Balogh E, Kaushik P, et al.
Diabetes Ther
. 2018 Oct;
9(6):2245-2257.
PMID: 30269224
Introduction: Many patients with diabetes may require high-dose insulin treatment to achieve target HbA1c level, but the prevalence, disease burden, and patient characteristics of the population remain unclear. We therefore...
6.
Valentine W, Van Brunt K, Boye K, Pollock R
Appl Health Econ Health Policy
. 2018 Mar;
16(3):357-366.
PMID: 29525908
Objective: The aim of the present study was to evaluate the cost effectiveness of rapid-acting analog insulin relative to regular human insulin in adults with type 1 diabetes mellitus in...
7.
Yu M, Van Brunt K, Milicevic Z, Varnado O, Boye K
Clin Ther
. 2017 Nov;
39(11):2284-2295.
PMID: 29110972
Purpose: This 28-week, randomized, double-blind study compared a once-weekly injection of dulaglutide 1.5 mg to placebo, both added to titrated once-daily insulin glargine (with or without metformin), in patients with...
8.
Van Brunt K, Pedersini R, Rooney J, Corrigan S
Diabetes Res Clin Pract
. 2017 Feb;
126:30-42.
PMID: 28189952
Aims: People with diabetes who use mealtime insulin (MTI) were surveyed about insulin wastage and injection habits when insufficient insulin remains in a disposable prefilled pen/cartridge to administer a full...
9.
Van Brunt K, Curtis B, Ivanyi T, Balogh E, Chalkiadaki C, MacLachlan S, et al.
Diabetes Ther
. 2016 Nov;
7(4):793-807.
PMID: 27796906
Introduction: Increasing emphasis is being placed on insulin use among patients with type 2 diabetes mellitus (T2DM). Basal-bolus (BB) therapy is regarded as the gold standard, but a high frequency...
10.
Wang T, Conrad K, Van Brunt K, Rees T
J Diabetes Sci Technol
. 2016 Feb;
10(4):923-31.
PMID: 26920640
Background: This study compared patient preference for Humalog® KwikPen™ 200 units/mL (insulin lispro; hereafter, IL 200 pen; Eli Lilly and Company, Indianapolis, IN) versus the Humalog KwikPen 100 units/mL (insulin...